Population Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
Soins et Santé Primaire, Centre for Research in Epidemiology and Population Health (CESP) INSERM 1018, INSERM, Villejuif, France.
BMJ Sex Reprod Health. 2021 Oct;47(4):e14. doi: 10.1136/bmjsrh-2020-200724. Epub 2020 Oct 22.
Unprecedented public health actions restricting movement and non-COVID related health services are likely to have affected abortion care during the pandemic in Europe. In the absence of a common approach to ensure access to this essential health service, we sought to describe the variability of abortion policies during the outbreak in Europe in order to identify strategies that improve availability and access to abortion in times of public health crises.
We collected information from 46 countries/regions: 31 for which country-experts completed a survey and 15 for which we conducted a desk review. We describe abortion regulations and changes to regulations and practice during the pandemic.
During COVID-19, abortions were banned in six countries and suspended in one. Surgical abortion was less available due to COVID-19 in 12 countries/regions and services were not available or delayed for women with COVID-19 symptoms in eleven. No country expanded its gestational limit for abortion. Changes during COVID-19, mostly designed to reduce in-person consultations, occurred in 13 countries/regions. Altogether eight countries/regions provided home medical abortion with mifepristone and misoprostol beyond 9 weeks (from 9 weeks+6 days to 11 weeks+6 days) and 13 countries/regions up to 9 weeks (in some instances only misoprostol could be taken at home). Only six countries/regions offered abortion by telemedicine.
The lack of a unified policy response to COVID-19 restrictions has widened inequities in abortion access in Europe, but some innovations including telemedicine deployed during the outbreak could serve as a catalyst to ensure continuity and equity of abortion care.
限制行动和非 COVID 相关医疗服务的前所未有的公共卫生措施可能会影响欧洲大流行期间的堕胎护理。在缺乏确保获得这项基本医疗服务的共同方法的情况下,我们试图描述欧洲大流行期间堕胎政策的变化,以确定在公共卫生危机时期增加和获得堕胎的策略。
我们从 46 个国家/地区收集信息:31 个国家/地区的国家专家完成了调查,15 个国家/地区进行了桌面审查。我们描述了堕胎法规以及大流行期间法规和实践的变化。
在 COVID-19 期间,有六个国家/地区禁止堕胎,一个国家/地区暂停堕胎。由于 COVID-19,有 12 个国家/地区的手术堕胎服务可用性降低,有 11 个国家/地区的堕胎服务对有 COVID-19 症状的妇女不可用或延迟。没有一个国家扩大了堕胎的妊娠限制。COVID-19 期间发生的变化主要旨在减少面对面咨询,在 13 个国家/地区发生。总共有八个国家/地区提供米非司酮和米索前列醇的家庭医疗堕胎,超过 9 周(从 9 周+6 天到 11 周+6 天),13 个国家/地区可达 9 周(在某些情况下只能在家中服用米索前列醇)。只有六个国家/地区提供远程医疗堕胎。
对 COVID-19 限制缺乏统一的政策应对,扩大了欧洲堕胎机会的不平等,但大流行期间部署的一些创新,包括远程医疗,可以成为确保堕胎护理连续性和公平性的催化剂。